ClinicalTrials.gg
RecruitingNCT06295900Updated Mar 6, 2024

The Effect of Aromatherapy Massage on Sleep Quality

An interventional study of Intervention 1 Group and Intervention 2 Group in Diabetes Mellitus, Respiratory Failure and Pneumonia, sponsored by Nilgün Erdoğan. Recruiting at 1 site in Turkey. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Nilgün Erdoğan · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 246 studies in Diabetes Mellitus with a site in Turkey — 37 open to participants now, 44 under way, 1 of them phase 3. Diabetes Mellitus · Turkey.

Planned enrollment
111th of 147
62 · median 90
Started
2024
with 24 others
No phase
92 of 246
22 open now
Primary completion
2024-12
later than 5 of 43 live
Registered
162nd of 246
by date

Among the 246 studies in Diabetes Mellitus with a site in Turkey, this one is the 111th largest by planned enrollment of the 147 interventional ones that give a count, is one of 25 that started in 2024, is one of 92 with no phase, reaches primary completion later than 5 of the 43 other live ones, and was the 162nd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

37 of the 246 studies in Diabetes Mellitus with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Diabetes Mellitus with a site in Turkey, or all of them as a file.
02

Study summary

Sleep disturbance is one of the most common complaints of patients admitted to ICU. Insufficient sleep in intensive care units may be associated with environmental reasons such as excessive light at night, loud warning sounds and mechanical ventilation alarms, as well as non-environmental factors, including the situation at the time of admission. Sleep assessment is subjective in nature, so it is difficult to perform in the ICU. Since communication with the patient is prevented, clear information about perceived rest and disturbing factors cannot be provided. For this reason, night rest is an issue that is often forgotten and ignored. This study applied a mixture of lavender, medicinal chamomile and neroli oil (in 20 ml of sweet almond oil; lavender oil 2 drops, medicinal chamomile 4 drops, neroli oil 6 drops) to patients who were monitored in intensive care on high-flow and oxygen, once a day for three days. This study will be conducted to determine the effect of aromatherapy massage applied for a total of 30 minutes on sleep quality.

03

Conditions studied

  • Diabetes Mellitus
  • Respiratory Failure
  • Pneumonia
  • Respiratory Disease
  • Stroke, Ischemic

Keywords

  • intensive care
  • sleep quality
  • aromatherapy massage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age and over,
  • Conscious patients,
  • Staying in intensive care for 24 hours or more,
  • Those with stable hemodynamic status,
  • Receiving O2 therapy,
  • Intubated patients, patients who have passed 24 hours after being extubated,
  • Those whose saturation level is 85 and above

Exclusion criteria

Exclusion Criteria:

  • Patients with peripheral neuropathy or quadriplegia,
  • Patients with open wounds on their body,
  • Patients receiving analgesia and sedation infusion,
  • Patients who are sedated,
  • Patients in delirium,
  • Patients with allergies detected before starting the application
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Intervention 1 Group

    In this group, application is made with chamomile, lavender and neroli oil.

    Other: Intervention 1 Group

  • Sham comparator
    Intervention 2 Group

    In this group, application is made with lavender oil.

    Other: Intervention 2 Group

  • Placebo comparator
    Placebo Control Group

    In this group, application is made only with almond oil.

    Other: Placebo Control Group

Interventions

  • OtherIntervention 1 Group

    20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.

  • OtherIntervention 2 Group

    It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.

  • OtherPlacebo Control Group

    It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.

06

What researchers measure

Primary outcomes

  1. Patient Introduction Form

    In the "Patient Introduction Form" prepared by the researcher based on the literature in order to obtain information about the characteristics of the patients who will constitute the sample, the patients' medical diagnosis, age, gender, chronic diseases, length of stay in intensive care, use of analgesic, sedative and hypnotic drugs used, normal sleep hours at night were included. There are questions about (sleep duration, daytime sleep, sleep hours, sleep aids used, etc.).

    Time frame: 1 year

Secondary outcomes

  1. Patient Follow-up Form

    The patient follow-up form was created by the researcher and will include the visual comparison sleep scale follow-up results, the effects of the application (whether side effects develop, its effect on the application area, the patient's condition, etc.) and the dosage of the hypnotic and sedative drugs the patient took in the intensive care unit during the study. The sleep score results of the patients will be recorded on the patient follow-up form by the nurses who collected the data of the study the morning after the application (08), and the effects of the application will also be recorded by the researcher.

    Time frame: 1 year

Other outcomes

  1. Visual Comparison Sleep Scale

    It was first developed by Snyder-Halpern and Verran (1988) in 1987 to evaluate the sleep quality of sick and healthy individuals. The scale consists of 15 questions categorized under three subscales: 'discomfort' (interruptions and delays in sleep), 'effectiveness' (how good sleep rejuvenates the individual) and 'completion' (napping). Disturbance questions include: 1) waking in the middle of sleep, 2) waking after sleep onset, 3) movement during sleep, 4) firmness of sleep, 5) quality of discomfort, 6) sleep latency, and 7) quality of latency. Efficacy questions include: 1) recovery after awakening, 2) subjective sleep quality, 3) sleep adequacy assessment, 4) total sleep time, and 5) total sleep time, calculated by adding total sleep time and waking after sleep onset. Each question is scored using a 100 mm visual analogue scale. For the 'disruption' and 'completion' subscales, higher scores indicate sleep disturbance and lower scores indicate better sleep.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2024, 11 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Mar 6, 2024
StartActual
Jan 5, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06295900
Lead sponsor
Nilgün Erdoğan
Responsible party
Nilgün Erdoğan (Principal Investigator, Nigde Omer Halisdemir University) — Sponsor-investigator
First posted
Mar 6, 2024
Start date
Jan 5, 2024
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Mar 6, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion